Fighting the Fracture Cascade: Evaluation and Management of Osteoporotic Fractures

References

• Cuddihy MT, Gabriel SE, Crowson CS, et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med. 2002; 162(4): 421–426.
   PubMedGoogle Scholar
• Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003; 163(17): 2052–2057.
   PubMed Web of Science ®Google Scholar
• Foley KA, Foster SA, Meadows ES, Baser O, Long SR. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007; 45(9): 902–906.
   PubMed Web of Science ®Google Scholar
• Florida Academy of Family Physicians. Osteoporosis Monograph 2007. www.fafp.org/documents/February_08/osteoporsis_monograph.pdf. Accessed July 23,2008.
   Google Scholar
• AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9(6): 544–564.
   PubMedGoogle Scholar
• Kanis JA, Johnell O. The burden of osteoporosis. J Endocrinol Invest. 1999; 22(8): 583–588.
   PubMedGoogle Scholar
• Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007; 21(1): 109–122.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7): 556–561.
   PubMed Web of Science ®Google Scholar
• Pasco JA, Sanders KM, Hoekstra FM, Henry MJ, Nicholson GC, Kotowicz MA. The human cost of fracture. Osteoporos Int. 2005; 16(12): 2046–2052
   PubMed Web of Science ®Google Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am. 2001; 27(1): 255–262.
   PubMedGoogle Scholar
• Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007; 22(3): 465–475.
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
   Google Scholar
• Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005; 353: 164–171.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35(2): 375–382.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3): 320–323.
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4): 721–739.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003; 921: 1–164.
   PubMed Web of Science ®Google Scholar
• International Society for Clinical Densitometry. Official Positions and Pediatric Official Positions. West Hartford, CT: ISCD; 2007.
   Google Scholar
• Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4): 385–397.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002; 77(5): 453–468.
   PubMed Web of Science ®Google Scholar
• Bonjour JP, Theintz G, Law F, et al. Peak bone mass. Osteoporos Int. 1994; 4(suppl 1): 7–13.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Osteoporosis: peak bone mass in women. www.niams.nih.gov/Health_Info/Bone/Osteoporosis/bone_mass. Accessed October 13, 2008.
   Google Scholar
• Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP. American College of Sports Medicine. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc. 2007; 39(10): 1867–1882.
   PubMed Web of Science ®Google Scholar
• Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007; 92(4): 1415–1423.
   PubMed Web of Science ®Google Scholar
• Moore C, Murphy MM, Keast DR, Holick MF. Vitamin D intake in the United States. J Am Diet Assoc. 2004; 104(6): 980–983.
   PubMedGoogle Scholar
• National Osteoporosis Foundation. What you should know about calcium. www.nof.org/prevention/calcium2.htm. Accessed October 16, 2008.
   Google Scholar
• Fosamax® (alendronate sodium) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; February 2008. www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf. Accessed October 14, 2008.
   Google Scholar
• Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of rise-dronate and alendronate in postmenopausal women. Gastroenterology. 2000; 119(3): 631–638.
   PubMed Web of Science ®Google Scholar
• Actonel® (risedronate sodium) [package insert]. Cincinnati, OH: Procter and Gamble Pharmaceuticals, Inc; April 2008. www.actonel.com/global/prescribinginformation.pdf. Accessed October 14, 2008.
   Google Scholar
• Boniva® (ibandronate sodium) [package insert], Nutley, NJ: Roche Laboratories Inc; August 2006. www.rocheusa.com/products/Boniva/PI.pdf. Accessed October 14, 2008.
   Google Scholar
• Boniva® (ibandronate sodium) [package insert], Nutley, NJ: Roche Laboratories Inc; February 2007. www.rocheusa.com/products/Boniva/Injection_PI.pdf. Accessed October 14, 2008.
   Google Scholar
• Reclast® (zoledronic acid) [package insert]. Stein, Switzerland: Novartis Pharma Stein AG; June 2008. www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf. Accessed October 14, 2008.
   Google Scholar
• Evista® (raloxifene HCL) [package insert], Indianapolis, IN: Eli Lilly and Company; December 2007. www.pi.lilly.com/us/evista-pi.pdf. Accessed October 14, 2008.
   Google Scholar
• Miacalcin® (calcitonin-salmon) [package insert]. Huningue, France: Novartis Pharma SAS; June 2006. www.pharma.us.novartis.com/product/pi/pdf/miacalcin_nasal.pdf. Accessed October 14, 2008.
   Google Scholar
• Miacalcin® (calcitonin-salmon) [package insert]. Stein, Switzerland: Novartis Pharma Stein AG; November 2002. www.pharma.us.novartis.com/product/pi/pdf/miacalcin_injection.pdf. Accessed October 14, 2008.
   Google Scholar
• Forteo® (teriparatide injection) [package insert]. Indianapolis, IN: Eli Lilly and Company; February 2008. www.pi.lilly.com/us/forteo-pi.pdf. Accessed October 14, 2008.
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041): 1535–1541.
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85(11): 4118–4124.
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14): 1344–1352.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18): 1809–1822.
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8): 1241–1249.
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004; 20(4): 433–439.
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004; 74(2): 129–135.
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1,2, and 3 years in postmenopausal women with osteoporosis. Bone. 2005; 37(5): 651–654.
   PubMedGoogle Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7): 637–645.
   PubMed Web of Science ®Google Scholar
• Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002; 162(10): 1140–1143.
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4): 267–276.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19): 1434–1441.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006(24);296: 2927–2938.
   Google Scholar
• Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004; 75(6): 462–468.
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10): 1479–1491.
   PubMed Web of Science ®Google Scholar
• Jeffcoat M, Watts NB. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. Gen Dent. 2008; 56(1): 96–102.
   PubMedGoogle Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96(23): 1751–1761.
   PubMedGoogle Scholar
• Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355(2): 125–137.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008: 11(1): 44–47.
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81 (8): 1013–1022.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006; 119(4 suppl 1): S12–S17.
   PubMed Web of Science ®Google Scholar